Tina-quant® Cystatin C

Supporting the early detection of chronic kidney disease

Tina-quant® Cystatin C

Supporting the early detection of chronic kidney disease


Chronic kidney disease (CKD) is an insidious disease with a dramatically increasing prevalence across the globe accompanied by a huge impact on healthcare budgets.1 Detecting chronic kidney disease at early stages allows for early intervention and thus has the potential to delay or even prevent the development of end-stage renal disease (ESRD) and related complications.2 Cystatin C is a marker with the ability to detect mild kidneyinsufficiency through subtle changes in the glomerular filtration rate (GFR).3 Therefore, cystatin C offers additional medical value versus the use of creatinine contributing to better patient cares.

Cystatin C

Determination of subtle changes in GFR is crucial in the early detection of CKD


Serum creatinine levels only begin to rise in CKD stage 3 when approximately 50 % of renal function is already lost (“creatinine-blind area”). Subtle changes in the GFR in CKD stages 1 and 2 – not detectable by creatinine-based measurements – can be determined by cystatin C due to its higher sensitivity and specificity.

Figure 1: Stages of chronic kidney disease according to NKF KDOQI4

Cystatin C graph 1

Highly sensitive and specific, unaffected by physical factors


Cystatin C is not affected by any physical factors such as muscle mass, age, gender or ethnicity. As a result, cystatin C shows a relatively high diagnostic sensitivity and specificity compared with creatinine, making it a reliable early marker of renal dysfunction. In a study of 93,000 patients, cystatin C-based estimation of GFR, correctly reclassified 42 % of patients with a creatinine-based estimation of GFR of 45 - 59 mL/min/1.73 to a “normal” risk group concerning end-stage renal disease and cardiovascular death.5

Figure 2: ROC analysis of cystatin C and creatinine3

Cystatin C graph 2

Tina-quant Cystatin C Gen.2 – excellent assay performance


Figure 3: Correlation between cobas c 501 and Siemens BN II cystatin C application. Highly developed turbidimetric detection technology delivers accurate results comparable to nephelometric measurement methods.6

Cystatin C graph 3

  1. Zhang, Q.L., Rothenbacher, D. (2008). Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 8: 117.
  2. James, M.T., Hemmelgarn, B.R., Tonelli, M. (2010). Early recognition and prevention of chronic kidney disease. Lancet 375, 1296-309.
  3. Artunc, F., Fischer, I.U., Risler, T., Erley, C.M. (2005). Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catherization. Int J Cardiol 102, 173-8.
  4. National Kidney Foundation Kidney Disease Outcomes Quality Initiative, www.kidney.org/professionals/kdoqi/.
  5. Cystatin C versus Creatinine in Determining Risk Based on Kidney Function Michael G. Shlipak, et al, N Engl J Med 2013; 369:932-43.
  6. Data on file at Roche (2011). Lotz J., Trummler M., Esmilaire L. Correlation study turbidimetry versus nephelometry. Turbidimetry setting new standards: Consolidation without compromise.